Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous adipose-derived mesenchymal stem cells (Regeneris Medical)
- Development stage
- Unknown
- Lead developer
- Regeneris Medical
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
Autologous adipose-derived mesenchymal stem cells (MSCs) are a type of cell therapy being investigated by Regeneris Medical for the treatment of respiratory compromise associated with COVID-19, including severe pneumonia and Acute Respiratory Distress Syndrome (ARDS). These cells are harvested from the patient's own adipose (fat) tissue, processed, and then administered intravenously. The therapeutic rationale is based on the immunomodulatory and anti-inflammatory properties of MSCs, which are thought to mitigate the cytokine storm—an overactive immune response characterized by the systemic release of pro-inflammatory cytokines. By reducing lung inflammation and promoting tissue repair, these cells aim to improve clinical outcomes and reduce the need for intensive respiratory support in hospitalized COVID-19 patients.
- Other names
- Autologous Adipose MSCsAutologous Adipose Derived Mesenchymal Cells
Beyond the preview
Go deeper on autologous adipose-derived mesenchymal stem cells (Regeneris Medical).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous adipose-derived mesenchymal stem cells (Regeneris Medical).